Synapse - Works

Results (115370)

Evaluation of a prognostic 23-gene expression panel in a set of 390 multiethnic Hodgkin lymphoma patients

Meeting Abstract

Colombo, A.; Wan, J. Y.; Jiang, A.; Aparicio, J.; Lam, E.; Aoki, T.; Song, J. Y.; Pullarkat, S.; Chao, C.; Mejia-Arangure, J. M.; more...
Blood (2023)

Fulltext@MSK | Save

Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed/refractory follicular lymphoma: Results from the phase 1/2 BRUIN study

Meeting Abstract

Shah, N. N.; Zinzani, P. L.; Wang, M. L.; Nasta, S. D.; Lech-Maranda, E.; Ogawa, Y.; Fakhri, B.; Kuss, B.; Miyashita, K.; Patel, K.; more...
Blood (2023)

Fulltext@MSK | Save

Heterogeneity in access and toxicity management of commercially available BCMA-directed CAR-T and Bispecific T-cell engager therapy among the international myeloma community

Meeting Abstract

Hassan, H.; Samur, M. K.; Cohen, A. D.; Moreau, P.; Otero, P. R.; Kumar, S. K.; Mateos, M. V.; Avigan, D.; Sperling, A. S.; Nadeem, O.; more...
Blood (2023)

Fulltext@MSK | Save

Sustained efficacy and safety with asciminib (ASC) after almost 4 years of median follow-up from ASCEMBL, a phase 3 study of ASC vs bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): An end of study treatment (EOS Tx) update, including results from switch population

Meeting Abstract

Mauro, M.; Minami, Y.; Hochhaus, A.; Lomaia, E.; Voloshin, S.; Turkina, A.; Kim, D. W.; Apperley, J. F.; Cortes, J.; Abdo, A. N. R.; more...
Blood (2023)

Fulltext@MSK | Save

CNS prophylaxis in adult ALL patients after stem cell transplantation: An EBMT survey on general practice

Meeting Abstract

Chiusolo, P.; Labopin, M.; Khvedelidze, I.; Baron, F.; Brissot, E.; Bazarbachi, A.; Bug, G.; Esteve, J.; Giebel, S.; Gorin, N. C.; more...
Blood (2023)

Fulltext@MSK | Save

EBV prevalence and overall survival in the Multi Ethnic Study of Hodgkin lymphoma (MESH)

Meeting Abstract

Lam, E.; Wan, J. Y.; Aparicio, J.; Pullarkat, S.; Colombo, A.; Song, J. Y.; Chao, C.; Mejia-Arangure, J. M.; Hernandez, B.; Jiang, A.; more...
Blood (2023)

Fulltext@MSK | Save

Trial in progress: A phase 1 study of KTX-1001, an oral, first-in-class, selective MMSET inhibitor in patients with relapsed and refractory multiple myeloma

Meeting Abstract

Berdeja, J. G.; Dingli, D.; Lonial, S.; Yee, A. J.; Chung, A.; Gasparetto, C.; Bergsagel, P. L.; Roy, V.; Abdallah, A. O.; Thanendrarajan, S.; more...
Blood (2023)

Fulltext@MSK | Save

AHOD2131: A randomized phase 3 response-adapted trial comparing standard therapy with immuno-oncology therapy for children and adults with newly diagnosed stage I and II classic Hodgkin lymphoma

Meeting Abstract

Henderson, T. O.; Hu, B.; Keller, F.; Pei, Q.; Wu, Y.; Hoppe, B.; Milgrom, S.; Yao, S.; Khan, N.; Roth, L. G.; more...
Blood (2023)

Fulltext@MSK | Save

PET4 response as an independent predictor of long-term outcomes in ECHELON2 (A+CHP vs. CHOP) in CD30+PTCL

Meeting Abstract

Iyer, S. P.; Mehta-Shah, N.; Advani, R. H.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domenech, E. D.; Pagani, C.; Kim, W. S.; Alpdogan, O.; more...
Blood (2023)

Fulltext@MSK | Save

Anti-leukemic activity of Luveltamab tazevibulin (LT, STRO-002), a novel Folate receptor-α (FR-α)-targeting antibody drug conjugate (ADC) in relapsed/refractory CBF2AT3::GLIS2 AML

Meeting Abstract

Williams, R.; Miller, L.; Massaro, S.; Krieger, E.; Pauly, M.; Nelson, C.; Johnson, R.; Welch, J. J. G.; Bhojwani, D.; Moghimi, B.; more...
Blood (2023)

Fulltext@MSK | Save